Since its inception, the European Union’s Unified Patent Court (UPC) has garnered significant interest from intellectual property stakeholders globally. Despite its promise of streamlined judicial procedures and high-quality decisions by panels of both legally and technically qualified judges, the UPC is still experiencing a high rate of opt-outs. This trend is particularly noticeable among large U.S.-based life science companies, which remain cautious about the court’s unpredictability. A detailed analysis by Sanjay Murthy and Christopher Tuinenga at McAndrews Held suggests that these companies’ strategies regarding UPC opt-outs are likely to continue in the same direction due to prevailing uncertainties.
For additional insights on why life science companies are approaching UPC opt-outs with caution, refer to the detailed analysis provided by Sanjay Murthy and Christopher Tuinenga at McAndrews Held.